Twist Bioscience Corp's (NASDAQ:TWST) Q4 sales increased 16.8% Y/Y to $66.9 million, beating the consensus of $63.45 million. 

The company's Q4 revenue exceeded the management guidance of $63 million-$64 million.

The company reported a EPS loss of $(0.81), better than the consensus of $(0.92). 

Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022.

Grew customer base to approximately 3,450 customers in fiscal 2023 versus approximately 3,300 in fiscal 2022.

Increased genes shipped to approximately 634,000 during fiscal 2023, compared with approximately 558,000 in fiscal 2022.

The guidance includes SynBio revenue of $113 million-$116 million, up 16%-18%, with NGS revenue of $147 million-$149 million, up 19%-20%, and Biopharma revenue of approximately $25 million, up 8%.

The company expects a gross margin of approximately 39%-40%.

Twist Bioscience expects Q1 FY24 revenue of $67 million-$68 million versus a consensus of $63.45 million, with a gross margin of around 38%-39%.

The company forecasts Q1 SynBio revenue of approximately $27 million, NGS revenue of $36 million-$37 million, and Biopharma revenue of approximately $4 million.

For Q4 FY24, the company anticipates revenue of approximately $78 million.

Price Action: TWST shares are up 21.21% at $23.11 on the last check Friday.

Photo Via Company